角膜病、青光眼、玻璃体及视网膜疾病的基础、临床和交叉研究

Basic, clinical and interdisciplinary research on corneal diseases, glaucoma, vitreous and retinal diseases

现任附属同济医院眼科主任、眼科教研室主任、眼科规培基地主任、同济大学医学院视觉科学与转化研究中心主任、同济大学医学院眼科研究所常务副所长

德国眼科学会会员、教育部高等学校教学指导委员会眼视光分会委员、中国医药教育协会智能眼科分会副主委、中国整形美容协会海峡两岸分会眼整形专委会副主委、上海市医学会眼科学分会常委兼秘书（眼底病学组副组长）、上海市免疫学会眼免疫专委会副主委、中国研究型医院协会眼科学分会常委、上海市中西医结合学会眼科学分会常委（眼底病学组组长）、TFOS中国区创始委员。

Currently serving as Director of the Department of Ophthalmology, Director of the Ophthalmology Teaching and Research Section, and Director of the Ophthalmology Standardized Training Base at Tongji Hospital Affiliated to Tongji University; Director of the Center for Vision Science and Translational Research, and Executive Deputy Director of the Institute of Ophthalmology at Tongji University School of Medicine.

He is a Member of the German Ophthalmological Society; Member of the Ophthalmology and Optometry Subcommittee, Higher Education Teaching Advisory Board of the Ministry of Education; Vice Chairman of the Intelligent Ophthalmology Branch, China Medical Education Association; Vice Chairman of the Ocular Plastic Surgery Special Committee, Cross-Strait Branch of Chinese Association of Plastics and Aesthetics; Standing Committee Member and Secretary (Deputy Group Leader of the Retinopathy Group) of the Ophthalmology Branch, Shanghai Medical Association; Vice Chairman of the Ocular Immunology Special Committee, Shanghai Society for Immunology; Standing Committee Member of the Ophthalmology Branch, Chinese Research Hospital Association; Standing Committee Member (Group Leader of the Retinopathy Group) of the Ophthalmology Branch, Shanghai Association of Integrated Traditional Chinese and Western Medicine; and Founding Member of TFOS China Chapter.

曾获全国白求恩式好医生、教育部新世纪优秀人才、上海市东方英才计划、上海市卫生系统优秀学科带头人、上海市高校优秀青年教师、同济大学师德师风优秀教师、同济大学倪天增教育奖、同济大学育才奖、同济大学2025年度“十大最具转化潜力”科技成果、同济大学攀登高层次A类人才、第八届医学家年会“十大医学贡献专家”等称号。

累计主持国家自然科学基金面上项目3项，校级及以上课题30余项，目前在研科研经费150余万元。带领团队牵头发布全国首个眼前后节联合手术相关团体标准和专家共识；在基础医学（Adv Sci，Pharmacol Res.等）、眼科学(Eye，IOVS等)、交叉学科（Information Fusion，IEEE TNNLS，BB等）领域期刊共52篇SCI论文、16篇中华系列论文；累计授权国际发明专利1项、国家发明专利19项、实用新型50余项，转化7项，荣获中国医疗器械创新创业大赛一等奖、长三角高价值专利运营大赛金奖等省部级以上奖励8项。

He has been awarded numerous honors and titles, including National Bethune-style Outstanding Physician, New Century Excellent Talents of the Ministry of Education, Shanghai Oriental Talents Program, Outstanding Academic Leader of Shanghai Health System, Outstanding Young University Teacher of Shanghai, Outstanding Teacher for Morality and Ethics of Tongji University, Ni Tianzeng Education Award of Tongji University, Talent Cultivation Award of Tongji University, the 2025 Top Ten Most Translational Potential Scientific and Technological Achievements of Tongji University, Top-Class Talents of the Climbing High-Level Talent Program of Tongji University, and the Top Ten Medical Contribution Experts at the 8th Annual Conference of Medical Experts.

He has presided over 3 General Programs funded by the National Natural Science Foundation of China and more than 30 research projects at the university and higher levels, with over 1.5 million RMB of ongoing research funding to date. Leading his team, he took the lead in issuing the nation’s first group standard and expert consensus on combined anterior and posterior segment ocular surgery. He has published 52 SCI papers in journals covering basic medicine (Advanced Science, Pharmacological Research, etc.), ophthalmology (Eye, IOVS, etc.), and interdisciplinary fields (Information Fusion, IEEE Transactions on Neural Networks and Learning Systems, Brain Behavior and Immunity, etc.), as well as 16 papers in Chinese Core Journal Series of the Chinese Medical Association. He has been granted 1 international invention patent, 19 national invention patents and more than 50 utility model patents, among which 7 patents have been successfully transformed. Additionally, he has won 8 provincial and ministerial-level awards, including the First Prize of China Medical Device Innovation and Entrepreneurship Competition and the Gold Award of the Yangtze River Delta High-Value Patent Operation Competition.